Recent Posts

 Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Sponsor_160x130

Aptahem is supporting Sepsisfonden

GSA-320x260

Aptahem is supporting Global Sepsis Alliance and is part of the World Sepsis Declaration